BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

39 related articles for article (PubMed ID: 38707952)

  • 1. Transformation of NSCLC to SCLC harboring EML4-ALK fusion with V1180L mutation after alectinib resistance and response to lorlatinib: A case report and literature review.
    Lingling X; Maoxi C; Wei Y; Jieting Z; Yuanyuan Y; Ning X
    Lung Cancer; 2023 Dec; 186():107415. PubMed ID: 37907052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lorlatinib for the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer.
    Yang J; Gong W
    Expert Rev Clin Pharmacol; 2019 Mar; 12(3):173-178. PubMed ID: 30657349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bilateral optic neuropathy associated with lorlatinib monotherapy for ALK-positive metastatic lung adenocarcinoma.
    Kong AW; Engelmann AR; Hosseini M; Bonelli L
    Am J Ophthalmol Case Rep; 2024 Jun; 34():102063. PubMed ID: 38707952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
    Solomon BJ; Besse B; Bauer TM; Felip E; Soo RA; Camidge DR; Chiari R; Bearz A; Lin CC; Gadgeel SM; Riely GJ; Tan EH; Seto T; James LP; Clancy JS; Abbattista A; Martini JF; Chen J; Peltz G; Thurm H; Ou SI; Shaw AT
    Lancet Oncol; 2018 Dec; 19(12):1654-1667. PubMed ID: 30413378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective treatment of advanced lung adenocarcinoma with paraneoplastic leukemoid reaction with Lorlatinib: a case report.
    Niu R; Zhang Y; Pang J; Zhou Q; Lei Y; Du Y
    Front Oncol; 2024; 14():1341233. PubMed ID: 38344203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Management of Adverse Events Associated with Lorlatinib.
    Bauer TM; Felip E; Solomon BJ; Thurm H; Peltz G; Chioda MD; Shaw AT
    Oncologist; 2019 Aug; 24(8):1103-1110. PubMed ID: 30890623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful treatment with lorlatinib in a patient with meningeal carcinomatosis of ALK-positive non-small cell lung cancer resistant to alectinib and brigatinib: A case report.
    Nakashima K; Demura Y; Kurokawa K; Takeda T; Jikuya N; Oi M; Tada T; Akai M; Ishizuka T
    Medicine (Baltimore); 2021 Oct; 100(39):e27385. PubMed ID: 34596160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study.
    Solomon BJ; Bauer TM; Mok TSK; Liu G; Mazieres J; de Marinis F; Goto Y; Kim DW; Wu YL; Jassem J; López FL; Soo RA; Shaw AT; Polli A; Messina R; Iadeluca L; Toffalorio F; Felip E
    Lancet Respir Med; 2023 Apr; 11(4):354-366. PubMed ID: 36535300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With
    Solomon BJ; Bauer TM; Ignatius Ou SH; Liu G; Hayashi H; Bearz A; Penkov K; Wu YL; Arrieta O; Jassem J; Calella AM; Peltz G; Polli A; Thurm H; Mok T
    J Clin Oncol; 2022 Nov; 40(31):3593-3602. PubMed ID: 35605188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postmarketing safety of anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA Adverse Event Reporting System (FAERS).
    Omar NE; Fahmy Soliman AI; Eshra M; Saeed T; Hamad A; Abou-Ali A
    ESMO Open; 2021 Dec; 6(6):100315. PubMed ID: 34864500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-Line Lorlatinib or Crizotinib in Advanced
    Shaw AT; Bauer TM; de Marinis F; Felip E; Goto Y; Liu G; Mazieres J; Kim DW; Mok T; Polli A; Thurm H; Calella AM; Peltz G; Solomon BJ;
    N Engl J Med; 2020 Nov; 383(21):2018-2029. PubMed ID: 33207094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ocular and orbital side effects of ALK inhibitors: a review article.
    Chelala E; Hoyek S; Arej N; Kattan J; Kourie HR; Baakliny J; Antoun J
    Future Oncol; 2019 Jun; 15(16):1939-1945. PubMed ID: 31140869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety issues with the ALK inhibitors in the treatment of NSCLC: A systematic review.
    Kassem L; Shohdy KS; Lasheen S; Abdel-Rahman O; Ali A; Abdel-Malek RR
    Crit Rev Oncol Hematol; 2019 Feb; 134():56-64. PubMed ID: 30771874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
    Shaw AT; Felip E; Bauer TM; Besse B; Navarro A; Postel-Vinay S; Gainor JF; Johnson M; Dietrich J; James LP; Clancy JS; Chen J; Martini JF; Abbattista A; Solomon BJ
    Lancet Oncol; 2017 Dec; 18(12):1590-1599. PubMed ID: 29074098
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.